Publications by authors named "John Radford"

100Publications

Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial.

PLoS One 2020 2;15(4):e0231027. Epub 2020 Apr 2.

King's College London and Guy's & St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, Kings College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0231027PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117720PMC
July 2020

The Role of e-Health in the Delivery of Care for Patients with Hematological Cancers: A Systematic Literature Review.

Telemed J E Health 2020 Sep 24;26(9):1093-1105. Epub 2020 Mar 24.

The Christie Patient Centred Research Team, The Christie School of Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/tmj.2019.0231DOI Listing
September 2020

Clinical and patient-reported outcomes in children with learning disabilities treated using the Hall Technique: a cohort study.

Br Dent J 2020 01;228(2):93-97

School of Dentistry, University of Dundee, Park Place, Dundee, DD1 4HR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41415-019-1166-xDOI Listing
January 2020

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma.

Blood Adv 2020 01;4(1):203-206

Division of Cancer Sciences, University of Manchester, National Institutes of Health Research Biomedical Research Centre Manchester Cancer Research Centre, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960465PMC
January 2020

Reply to H.J.A. Adams et al and C. Kobe et al.

J Clin Oncol 2019 12 30;37(34):3325-3326. Epub 2019 Sep 30.

Sally F. Barrington, MBBS, MSc, Kings College London, London, United Kingdom; Elizabeth H. Phillips, MB and Nicholas Counsell, MSc, University College London, London, United Kingdom; and John Radford, MD, University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02056DOI Listing
December 2019

Silver diamine fluoride for managing carious lesions: an umbrella review.

BMC Oral Health 2019 07 12;19(1):145. Epub 2019 Jul 12.

School of Dentistry, University of Dundee, Park Place, Dundee, DD1 4HR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12903-019-0830-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626340PMC
July 2019

Discussing factors associated with quality of life in cancer follow-up appointments: a preliminary test of a pragmatic model for clinical practice.

Clin Rehabil 2019 Apr 24;33(4):762-772. Epub 2018 Dec 24.

6 School of Health Sciences, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269215518820093DOI Listing
April 2019

Letter comments on a published article in the New England Journal of Medicine.

Eur J Cancer 2018 11 23;104:250-251. Epub 2018 Oct 23.

Institute of Cancer Sciences, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.09.020DOI Listing
November 2018

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

J Clin Oncol 2018 08 1;36(23):2395-2404. Epub 2018 Jun 1.

Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.8960DOI Listing
August 2018

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

J Clin Oncol 2018 08 31;36(23):2405-2412. Epub 2018 May 31.

Ajay K. Gopal, The University of Washington; Ajay K. Gopal, Fred Hutchinson Cancer Research Center, Seattle, WA; Stephen J. Schuster, Abramson Cancer Center of the University of Pennsylvania, Philadelphia; Jing-Zhou Hou, University of Pittsburgh Medical Center; Jing-Zhou Hou, University of Pittsburgh Cancer Institute, Pittsburgh; Rajendra N. Damle, Michael Schaffer, and Sriram Balasubramanian, Janssen Research & Development, Spring House, PA; Nathan H. Fowler, The University of Texas MD Anderson Cancer Center, Houston, TX; Judith Trotman, Concord Hospital, University of Sydney, Sydney, New South Wales; Andrew Spencer, Alfred Hospital-Monash University, Melbourne, Victoria; James Morton, Haematology and Oncology Clinics of Australia, Milton, Queensland, Australia; Georg Hess, Johannes Gutenberg-University, Mainz, Germany; Abdulraheem Yacoub, Kansas University Medical Center, Kansas City, KS; Michael Lill, Cedars-Sinai Medical Center, Los Angeles, CA; Peter Martin, Weill Cornell Medical College, Cornell University, New York, NY; Umberto Vitolo, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy; John Radford, University of Manchester; John Radford, Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Dolores Caballero, Hospital Clínico Universitario, Salamanca, Spain; Sanjay Deshpande, Gary J. Gartenberg, and Shean-Sheng Wang, Janssen Research & Development, Raritan, NJ; Jessica Vermeulen, Janssen Research & Development, Leiden, the Netherlands; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; and Gilles Salles, Hospices Civils de Lyon-Université de Lyon, Pierre-Bénite cedex, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.8853DOI Listing
August 2018

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.

JAAD Case Rep 2018 Apr 23;4(3):229-231. Epub 2018 Feb 23.

Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525126173023
Publisher Site
http://dx.doi.org/10.1016/j.jdcr.2017.09.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909477PMC
April 2018

Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.

N Engl J Med 2018 04;378(16):1560-1561

University of Manchester, Manchester, United Kingdom

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1802363DOI Listing
April 2018

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

N Engl J Med 2018 01 10;378(4):331-344. Epub 2017 Dec 10.

From the University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, Canada (J.M.C., K.J.S.); the Department of Hematology, Jagiellonian University, Krakow (W.J.), the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw (E.L.-M.), the Department of Hematology and Transfusion Medicine, Center of Postgraduate Medical Education, Warsaw (E.L.-M.), the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.), and the Department of Lymphoid Malignancy, the Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw (J.W.) - all in Poland; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (D.J.S., A.Y.); the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the Division of Hematology and Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea (W.S.K.); Research Innovation and Statistics, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); Petrov Research Institute of Oncology, St. Petersburg, Russia (S.A.); the Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen (Á.I.), and the Department of Hematology, National Institute of Oncology, Budapest (A.R.) - both in Hungary; the Department of Advanced Biomedical Science, Federico II University Hospital, Naples (M.P.), and the Institute of Hematology Seràgnoli, University of Bologna, Bologna (P.L.Z.) - both in Italy; the Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston (Y.O.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (T.F.); the Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis (N.L.B.); the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA (R.C.); the Department of Hematology-Oncology, Barbara Ann Karmanos Cancer Center, Detroit (R.R.); Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton (D.C.), and the Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester (J.R.) - both in the United Kingdom; the Department of Clinical Development, Seattle Genetics, Bothell, WA (N.C.J., E.S.); and Oncology Clinical Research (J.S., H.A.J., D.H.) and Global Biostatistics (R.L.), Millennium Pharmaceuticals, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1708984DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819601PMC
January 2018

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

J Clin Oncol 2017 Jul 25;35(19):2125-2132. Epub 2017 Apr 25.

Robert Chen, City of Hope National Medical Center, Duarte, CA; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Nathalie A. Johnson, Jewish General Hospital, Montreal, Canada; Pauline Brice, Hôpital Saint-Louis, Paris; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; John Radford, The University of Manchester and Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Daniel Molin, Uppsala University, Uppsala, Sweden; Theodoros P. Vassilakopoulos, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece; Akihiro Tomita, Nagoya University Graduate School of Medicine, Nagoya, Japan; Bastian von Tresckow, University Hospital Cologne, Cologne, Germany; Yinghua Zhang, Alejandro D. Ricart, and Arun Balakumaran, Merck, Kenilworth, NJ; Craig H. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791843PMC
July 2017

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

J Clin Oncol 2017 Feb 28;35(5):544-551. Epub 2016 Dec 28.

Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.0198DOI Listing
February 2017

Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.

Br J Haematol 2017 12 22;179(5):841-843. Epub 2016 Jul 22.

Department of Medical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14257DOI Listing
December 2017

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

N Engl J Med 2016 Jun;374(25):2419-29

From the Cancer Research UK Centre, University of Southampton, Southampton (P.J.), Cancer Research UK and University College London Cancer Trials Centre (A.K., P.P., T.R., L.S., P.S.) and the PET Imaging Centre, King's College London, King's Health Partners, St. Thomas' Hospital (M.O., Z.V., S.B.), London, the Department of Haematology, Lincoln County Hospital, Lincoln (G.S.), and the Department of Medical Oncology, Christie Hospital, Manchester (J.R.) - all in the United Kingdom; the Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena (M. Federico, A. Franceschetto, S.L.), the Department of Hematology, San Martino University Hospital, Genoa (A.C.), and Arcispedale Santa Maria Nuova-Istituti di Ricovero e Cura a Carattere Scientifico, Reggio Emilia (S.L.) - all in Italy; the Department of Medical Oncology, Oslo University Hospital, Oslo (A. Fosså); the Department of Haematology, Auckland City Hospital, Auckland, New Zealand (L.B.); the Department of Hematology, Aarhus University Hospital, Aarhus, Denmark (F.A.); the Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden (G.E.); and the Department of Molecular Imaging, Royal Prince Alfred Hospital (M. Fulham), and Concord Repatriation General Hospital, University of Sydney (J.T.), Sydney.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236PMC
June 2016

Treatment of Hodgkin lymphoma in older patients.

Authors:
John Radford

Blood 2015 Dec;126(26):2768-9

MANCHESTER ACADEMIC HEALTH SCIENCE CENTRE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-671388DOI Listing
December 2015

Second Cancers after Treatment for Hodgkin's Lymphoma--Continuing Cause for Concern.

N Engl J Med 2015 Dec;373(26):2572-3

From the University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom (J.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1511947DOI Listing
December 2015

Current knowledge and future research directions in treatment-related second primary malignancies.

EJC Suppl 2014 Jun 29;12(1):5-17. Epub 2014 May 29.

Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcsup.2014.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250537PMC
June 2014

PET-Directed Therapy for Hodgkin's Lymphoma.

N Engl J Med 2015 07;373(4):392

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1506340DOI Listing
July 2015

XVI. Early stage Hodgkin lymphoma.

Authors:
John Radford

Hematol Oncol 2015 Jun;33 Suppl 1:84-6

Institute of Cancer Sciences, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2224DOI Listing
June 2015

QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma.

J Mol Diagn 2015 Jul 14;17(4):402-11. Epub 2015 May 14.

Lymphoma Translational Research Group, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom; The Department of Medical Oncology, Christie National Health Service Foundation Trust, Manchester, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2015.03.010DOI Listing
July 2015

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

N Engl J Med 2015 Apr;372(17):1598-607

From the Institute of Cancer Sciences, University of Manchester, and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester (J.R., T.I.), Cancer Research UK and University College London Cancer Trials Centre, Cancer Institute, University College London (N.C., B.P., P.S.), St. Georges Hospital, University of London (R.P.), St. Bartholomew's Hospital (A.L.), and the PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital (M.O., S.B.), London, the University of Sheffield and Weston Park Hospital, Sheffield (B.H.), Cancer Research UK Centre, Southampton (P.J.), Norfolk and Norwich University Hospital, Norwich (J.W.), Aberdeen Royal Infirmary, Aberdeen (D.C.), Nottingham City Hospital, Nottingham (A.M.), Queen's Hospital, Romford (A.B.), Royal Cornwall Hospital NHS Trust, Truro (A.K.), and the Cancer Centre, Mount Vernon Hospital, Northwood (P.H.) - all in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408648DOI Listing
April 2015

A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.

Br J Haematol 2015 Sep 26;170(6):886-90. Epub 2015 Feb 26.

Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13333DOI Listing
September 2015

Risk of premature menopause after treatment for Hodgkin's lymphoma.

J Natl Cancer Inst 2014 Sep 19;106(9). Epub 2014 Aug 19.

Divisions of Genetics and Epidemiology (AJS, RC), Breast Cancer Research (AJS) and Radiotherapy (AH), Institute of Cancer Research, Sutton, UK; University of Manchester and Christie NHS Foundation Trust, Manchester, UK (JR); Gastrointestinal Unit, Royal Marsden Hospital, Sutton, UK (DC); Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK (IS); Cancer Research UK Medical Oncology Unit, St. Bartholomew's Hospital, London, UK (TAL); Cancer Centre, Mount Vernon Hospital, Middlesex, UK (PJH); St. James Institute of Oncology, Leeds, UK (DG); Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK (HHL); Bristol Haematology and Oncology Centre, Bristol, UK (SJF); Addenbrooke's Hospital, Cambridge, UK (MVW); Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK (BWH); Guy's and St. Thomas, London, UK (SJH); Department of Haematology, University College Hospital, London, UK (DCL); Southampton General Hospital, Southampton, UK (AB); Queen Elizabeth Hospital, Birmingham, UK (AMS). The England and Wales Hodgkin Lymphoma Follow-up Group includes the authors of this article plus: Gabriel Anghel, Lincoln Hospital; Brian Attock, North Devon District Hospital; Jane Barrett, Royal Berkshire Hospital; Andrew Bell, Poole Hospital; Kim Benstead, Cheltenham General Hospital; Eric M. Bessell, Nottingham University Hospital; Ashoke Biswas, Royal Preston Hospital; Norbert Blesing, Great Western Hospital, Swindon; Caroline Brammer, New Cross Hospital, Wolverhampton; Jill Brock, Clatterbridge Centre for Oncology; Alison Brownell, Queens Hospital, Romford; A. Murray Brunt, University Hospital of North Staffordshire; Peter B. Coates, Queen Elizabeth Hospital, King's Lynn; Matthew P. Collinson, Royal Cornwall Hospital; Neville Davidson, Essex County Hospital; Sian Davies, North Middlesex University Hospital; Ian Fentiman, Guy's Hospital; Eve Gallop-Evans, Velindre Hospital; Angel Garcia, Glan Clwyd Hospital; Andrew Goodman, Royal Devon and Exeter Hospital; Ad

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju207DOI Listing
September 2014

Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).

Oncologist 2014 Mar 24;19(3):291-8. Epub 2014 Feb 24.

Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy; Department of Radiation Oncology, Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Canada; Auckland Hospital, Auckland, New Zealand; Christie Hospital, Manchester, United Kingdom; Seoul National University Hospital, Seoul, Korea; Korea Cancer Center Hospital, Seoul, Korea; Division of Hematology, European Institute of Oncology, Milan, Italy, Wesley Research Institute, Brisbane, Australia; Northern Centre for Cancer, New Castle, United Kingdom; Royal Prince Alfred Hospital, Sydney, Australia; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Premion and Bond University, Tugun, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958453PMC
March 2014

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

J Clin Oncol 2014 Jan 2;32(3):212-8. Epub 2013 Dec 2.

Tim M. Illidge, Sam Mayes, John A. Radford, W. David J. Ryder, Manchester Academic Health Science Centre, University of Manchester; Jill Tipping, Maureen Zivanovic, Christie Hospital NHS Foundation Trust, Manchester; Ruth Pettengell, St. George's, University of London, London; Andrew T. Bates, Southampton University Hospitals NHS Foundation Trust, Southampton; Mike Bayne, Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; Steven Le Gouill, Centre Hospitalier Universitaire Nantes; Françoise Kraeber-Bodere, Caroline Bodet-Milin, University Hospital-ICO-CRCNA INSERM U892, Nantes; Emmanuel Malek, Damien Huglo, Hospitalier Universitaire Lille; Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Fabrice Jardin, Centre Henri Becquerel, Rouen; Manuel Bardies, Centre de Recherche en Cancérologie de Toulouse, Faculté de Médecine de Toulouse-Rangueil, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.3110DOI Listing
January 2014

De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.

J Clin Oncol 2014 Feb 12;32(4):282-7. Epub 2013 Nov 12.

Paul A. Fields, Guys and St Thomas' and King's College Hospitals; William Townsend, Nicholas Counsell, Paul Smith, and Nadjet El-Mehidi, Cancer Research UK and University College London Cancer Trials Centre; David C. Linch, University College London Hospital; David Cunnningham, Royal Marsden Hospital, London; Andrew Webb, Royal Sussex Cancer Centre, Brighton; Christopher Pocock, Kent and Canterbury Hospital, Kent; Andrew Jack, St James Hospital, Leeds; Peter W. Johnson, Southampton General Hospital, Southampton; and John Radford, Christie Hospital, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.7586DOI Listing
February 2014

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

Blood 2013 Aug 10;122(7):1137-43. Epub 2013 Jul 10.

The University of Manchester and Christie National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-01-481341DOI Listing
August 2013

A statistical framework for analyzing hypothesized interactions between cells imaged using multispectral microscopy and multiple immunohistochemical markers.

J Pathol Inform 2013 30;4(Suppl):S4. Epub 2013 Mar 30.

Centre for Imaging Sciences, Institute for Population Health, The University of Manchester, Manchester, United Kingdom. ; The University of Manchester Biomedical Imaging Institute, The University of Manchester, Manchester, United Kingdom. ; Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2153-3539.109856DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678742PMC
June 2013

PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome.

J Clin Pathol 2013 Sep 11;66(9):764-7. Epub 2013 Jun 11.

The Medical School, The University of Manchester, Manchester, Greater Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2013-201461DOI Listing
September 2013

Treatment for early-stage hodgkin lymphoma: has radiotherapy had its day?

Authors:
John Radford

J Clin Oncol 2012 Nov 24;30(31):3783-5. Epub 2012 Sep 24.

The University of Manchester and the Christie National Health Service Foundation Trust, Manchester M20 4BX, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.43.2773DOI Listing
November 2012

Burkitt's lymphoma of an ileal pouch following restorative proctocolectomy.

Inflamm Bowel Dis 2012 Aug 31;18(8):E1596-7. Epub 2012 Jan 31.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ibd.21918DOI Listing
August 2012

Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.

J Clin Oncol 2011 Nov 3;29(31):4096-104. Epub 2011 Oct 3.

Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.34.8268DOI Listing
November 2011

Development of the Dundee Caries Risk Assessment Model (DCRAM)--risk model development using a novel application of CHAID analysis.

Community Dent Oral Epidemiol 2012 Feb 12;40(1):37-45. Epub 2011 Aug 12.

Kings Cross Health and Community Care Centre, Dundee, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0528.2011.00630.xDOI Listing
February 2012

YY1 expression predicts favourable outcome in follicular lymphoma.

J Clin Pathol 2011 Feb 25;64(2):125-9. Epub 2010 Nov 25.

School of Cancer and Enabling Sciences, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jcp.2010.078188DOI Listing
February 2011

Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519).

J Clin Oncol 2010 Jul 24;28(20):3352-9. Epub 2010 May 24.

University of Southampton, Medical Research Council (MRC) Clinical Trials Unit, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.0323DOI Listing
July 2010

Trainee written records: What's wrong? What's right? It depends!

Med Teach 2010 ;32(2):184-5

View Article

Download full-text PDF

Source
May 2010

Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays.

Biotechniques 2009 Jul;47(1):587-96

Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2144/000113169DOI Listing
July 2009

Limited-stage disease: optimal use of chemotherapy and radiation treatment.

Authors:
John Radford

Hematology Am Soc Hematol Educ Program 2008 :321-5

Cancer Research UK Department of Medical Oncology, Christie Hospital and The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2008.1.321DOI Listing
July 2009

The ranibizumab saga of drug profiteering.

BMJ 2008 Sep 3;337:a1532. Epub 2008 Sep 3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmj.a1532DOI Listing
September 2008

Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.

Blood 2008 May 3;111(9):4764-70. Epub 2008 Jan 3.

Department of Histopathology and Manchester Molecular Diagnostic Center, Manchester Royal Infirmary, Central Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-10-115915DOI Listing
May 2008